For research use only. Not for therapeutic Use.
DC-BPi-03（Cat No.:I042291）is a novel compound in preclinical development designed to target and modulate immune responses, particularly in the context of cancer immunotherapy. It is a small molecule that enhances the activity of dendritic cells (DCs), which are critical for initiating immune responses. By activating DCs and boosting their ability to present antigens to T-cells, DC-BPi-03 aims to improve the body’s ability to recognize and attack tumor cells. It shows potential in enhancing the effectiveness of cancer vaccines and immunotherapies, particularly in tumors that evade immune detection, providing promising therapeutic benefits.
| Catalog Number | I042291 |
| CAS Number | 2758411-46-8 |
| Synonyms | 6-(1H-indol-5-yl)-N-methyl-2-methylsulfonylpyrimidin-4-amine |
| Molecular Formula | C14H14N4O2S |
| Purity | ≥95% |
| IUPAC Name | 6-(1H-indol-5-yl)-N-methyl-2-methylsulfonylpyrimidin-4-amine |
| InChI | InChI=1S/C14H14N4O2S/c1-15-13-8-12(17-14(18-13)21(2,19)20)9-3-4-11-10(7-9)5-6-16-11/h3-8,16H,1-2H3,(H,15,17,18) |
| InChIKey | RTONKOFFKFVXAW-UHFFFAOYSA-N |
| SMILES | CNC1=NC(=NC(=C1)C2=CC3=C(C=C2)NC=C3)S(=O)(=O)C |
